文献速递消化系统肿瘤

DNA修复相关基因的遗传变异预测难治性转移性结直肠癌患者接受TAS-102的疗效

Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
PubMed 文献 · Ann Oncol · 2017-01-01

本研究分析了三个队列共233例样本,评估同源重组和细胞周期检查点通路基因的单核苷酸多态性与TAS-102疗效的关系。在评估队列中,ATM rs609429携带G等位基因者总生存期较长,XRCC3 rs861539携带A等位基因者无进展生存期和总生存期均较长;验证队列中ATM rs609429的G等位基因与较长生存相关。作者认为同源重组通路的遗传变异可能预测接受TAS-102的mCRC患者的临床结局。

要点

  • 评估队列中ATM rs609429携带G等位基因者总生存期长于C/C型(8.7 vs 4.4个月)。
  • 评估队列中XRCC3 rs861539携带A等位基因者PFS和OS均长于G/G型。
  • 验证队列中ATM rs609429携带G等位基因者OS和PFS较长。

核心结论

  • 同源重组通路的遗传变异可能预测接受TAS-102的难治性转移性结直肠癌患者的临床结局。

研究设计与样本

  • 分析三个队列共233例样本的基因组DNA:评估队列52例接受TAS-102,验证队列129例接受TAS-102,对照队列52例接受瑞戈非尼。
  • 采用PCR直接测序分析同源重组基因(ATM、BRCA1、BRCA2、XRCC3、FANCD2、H2AX、RAD51)和细胞周期检查点基因(ATR、CHEK1、CHEK2、CDKN1A、TP53、CHE1、PIN1、PCNA)的单核苷酸多态性。

主要发现

  • 评估队列单因素分析:ATM rs609429携带G等位基因者总生存期长于C/C型(8.7 vs 4.4个月,HR 0.37,95%CI 0.14-0.99,P=0.022)。
  • 评估队列单因素分析:XRCC3 rs861539携带A等位基因者无进展生存期(3.8 vs 2.3个月,HR 0.44,95%CI 0.21-0.92,P=0.024)和总生存期(15.6 vs 6.3个月,HR 0.25,95%CI 0.08-0.79,P=0.012)均长于G/G型。
  • 多因素分析中ATM rs609429对总生存期仍有统计学意义(P=0.020)。
  • 验证队列中ATM rs609429携带G等位基因者总生存期和无进展生存期较长;XRCC3 rs861539的G/A变异型总生存期较长,但无统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tri-phosphorylated trifluridine (FTD) incorporation into DNA is TAS-102's main anti-tumor action. We tested whether genetic polymorphisms in homologous recombination (HR) and cell cycle checkpoint pathway for DNA repair is associated with outcomes in refractory metastatic colorectal cancer (mCRC) patients treated with TAS-102. PATIENTS AND METHODS: We analyzed genomic DNA extracted from 233 samples of three cohorts: an evaluation cohort of 52 patients receiving TAS-102, a validation cohort of 129 patients receiving TAS-102 and a control cohort of 52 patients receiving regorafenib. Single nucleotide polymorphisms of genes involved in HR (ATM, BRCA1, BRCA2, XRCC3, FANCD2, H2AX, RAD51) and cell cycle checkpoint (ATR, CHEK1, CHEK2, CDKN1A, TP53, CHE1, PIN1, PCNA) were analyzed by PCR-based direct sequencing. RESULTS: In univariate analysis for the evaluation cohort, patients with any G allele in ATM rs609429 had longer overall survival (OS) than those with the C/C variant (8.7 vs. 4.4 months, HR 0.37, 95% CI: 0.14-0.99, P = 0.022). Patients carrying any A allele in XRCC3 rs861539 had significantly longer progression-free survival (PFS) (3.8 vs. 2.3 months, HR 0.44, 95% CI: 0.21-0.92, P = 0.024) and OS (15.6 vs. 6.3 months, HR 0.25, 95% CI: 0.08-0.79, P = 0.012) than those with the G/G variant. In multivariable analysis, ATM rs609429 remained significant for OS (P = 0.020). In the validation cohort, patients having ATM rs609429 with any G allele showed longer OS and PFS; the G/A variant in XRCC3 rs861539 showed longer OS, though without statistical significance. CONCLUSION: Genetic variants in the HR pathway may predict clinical outcome in mCRC patients receiving TAS-102.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Suenaga M, Schirripa M, Cao S, et al. Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Ann Oncol. 2017. PMID: 28453695. doi:10.1093/annonc/mdx035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。